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Abstract Objective: To investigate
the effect of one single bolus of eto-
midate used for intubation on adrenal
function in children with meningo-
coccal sepsis. Design: Retrospective
study conducted between 1997 and
2004. Setting: University-affiliated
paediatric intensive care unit (PICU).
Patients and participants: Sixty
children admitted to the PICU with
meningococcal sepsis, not treated
with steroids. Interventions: Adrenal
hormone concentrations were deter-
mined as soon as possible after PICU
admission, and after 12 h and 24 h. To
assess disease severity, PRISM score
and selected laboratory parameters
were determined. Measurements
and main results: On admission,
before blood was drawn, 23 children
had been intubated with etomidate,
8 without etomidate and 29 were
not intubated. Children who were
intubated had significantly higher
disease severity parameters than those
not intubated, whereas none of these
parameters significantly differed
between children intubated with or
without etomidate. Children who
received etomidate had significantly
lower cortisol, higher ACTH and
higher 11-deoxycortisol levels than
those who did not receive etomi-
date. Arterial glucose levels were
significantly lower in children who
were intubated with etomidate than
in non-intubated children. When chil-
dren were intubated with etomidate,
cortisol levels were 3.2 times lower
for comparable 11-deoxycortisol
levels. Eight children died, seven
of whom had received etomidate.
Within 24 h cortisol/ACTH and
cortisol/11-deoxycortisol ratios in-
creased significantly in children
who received etomidate, but not
in children who did not, resulting
in comparable cortisol/ACTH ra-
tios with still significantly lowered
cortisol/11-deoxycortisol ratios 24 h
after admission. Conclusions: Our
data imply that even one single bolus
of etomidate negatively influences
adrenal function for at least 24 h.
It might therefore increase risk of
death.
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Introduction
Stimulation of the hypothalamic-pituitary adrenal axis is
one of the most important hormonal reactions to critical
illness [1]. The anaesthetic drug etomidate is known to
inhibit adrenal function by mainly impeding the enzyme
11β-hydroxylase, the last step in the biosynthesis of cor-
tisol, resulting in increased levels of 11-deoxycortisol in
relation to cortisol [2] (Fig. 1). Since long-term etomidate
use has resulted in increased mortality, etomidate has
been withdrawn from long-term sedation regimens [3].
Etomidate, however, remained a first-line anaesthetic
agent in the setting of rapid sequence intubation, because
it has a favourable cardiopulmonary profile. One single
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Fig. 1 A schematic
representation of
steroidogenesis in the human
adrenal gland and the effect of
etomidate. Etomidate inhibits
11β-hydroxylase (CYP11B1),
11β- and 18-hydroxylase
(CYP11B2) and cholesterol
side-chain cleavage enzyme
system (CYP11A) (shaded) with
decreasing effectiveness.
Decreased CYP11B1 activity
will lead to lower levels of
cortisol and increased levels of
the upstream precursor
11-deoxycortisol. Decreased
CYP11B2 will lead to lower
aldosterone and higher
11-deoxycorticosterone levels,
whereas decreased CYP11A
will lead to generally decreased
steroidogenesis. 3β-HSD, 3β-
hydroxysteroid-dehydrogenase;
CYP21, 21-hydroxylase;
CYP17, 17-hydroxylase and
17, 20-lyase
bolus of etomidate was assumed by many intensive care
physicians to give only transient, clinically non-relevant
hormonal changes [4–6]. This assumption was mainly
based on small studies in healthy adults undergoing
elective surgery and may not be applicable in children
with septic shock, who are at risk for adrenal insufficiency.
We have previously shown that children dying from
meningococcal septic shock showed signs of inappropriate
adrenal function on PICU admission, i.e. relatively low
cortisol levels and extremely high adrenocorticotropic
hormone (ACTH) levels, which related independently to
parameters of disease severity and the use of one single
bolus of etomidate for rapid sequence intubation [7]. The
aim of this study was to examine the effect that etomidate
exerted on adrenal function during the first 24 h after PICU
admission in our cohort of children with meningococcal
sepsis.
Materials and methods
Patients
The group consisted of 69 previously healthy children (42
boys and 27 girls) consecutively admitted to the PICU of
the Erasmus MC–Sophia Children’s Hospital, with a clini-
cal picture of meningococcal sepsis, defined as sepsis with
petechiae and/or purpura as described previously [8–10].
Blood cultures revealed Neisseria meningitidis in 58 chil-
dren. Nine children who received corticosteroid therapy
for suspected adrenal insufficiency before admission were
excluded. Children who received corticosteroid therapy
after admission were included until they received cortico-
steroids. The lack of research staff to ensure an adequate
24-h stand-by service necessitated two study periods: from
October 1997 to October 1999 and from October 2001
to January 2004. The study was approved by the local
medical ethics committee and adhered to the tenets of the
Declaration of Helsinki.
Concomitant therapy
Concomitant therapy on admission included antibiotics
(cefotaxime) and administration of fluids in all 60 children
and inotropics in 51 children. On admission 31 children
were mechanically ventilated, whereas 29 children were
not. Mechanically ventilated children were intubated
at a median of 2 h and 40 min (range 5 min to 7 h)
before study enrolment with etomidate (n = 23) or with
combinations of opiate agonists, propofol, ketamine or
midazolam (n = 8). The median dose of the etomidate
bolus was 0.29 mg/kg (range 0.20–0.67 mg/kg) and was
significantly higher in children who died than in those
who survived (0.46 vs 0.29, p = 0.038). The sedatives and
doses used for rapid-sequence intubation depended on the
physicians’ choice. After admission four more children
were intubated with etomidate. Mechanically ventilated
children were all intubated for their clinical status only
and were sedated with benzodiazepines and/or morphine.
On admission, patients received intravenous glucose at
a rate of 4–6 mg/kg/min.
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Clinical parameters
Disease severity was determined using the Pediatric Risk
of Mortality score (PRISM II) [11] during the first 6 h of
admission. We recorded etomidate use, respiratory and in-
otropic support, quantified with vasopressor score of Wer-
novsky on admission [12].
Collection of blood samples and analysis
Arterial blood samples were obtained as soon as possible
after admission and at 12 h and 24 h thereafter for determi-
nation of ACTH, 11-deoxycortisol, cortisol, glucose, lac-
tate and interleukin (IL)-6 [8, 13].
Statistics
Results are expressed as medians unless specified other-
wise. We used Mann–Whitney U, chi-square or Fisher’s
exact test, Spearman’s correlation coefficient (r) and anal-
ysis of covariance (ANCOVA). The graph of the course of
cortisol/ACTH ratios was constructed using mixed-model
analysis of variance. Two-tailed p-values of < 0.05 were
considered statistically significant.
Results
Clinical parameters on admission
Children who had been intubated before admission,
independently of etomidate use, had significantly higher
Table 1 Patients’ characteristics and adrenal function on admission according to intubation and etomidate use
Reference values Intubated with Intubated without Not intubated
etomidate (n = 23) etomidate (n = 8) (n = 29)
Age (years) 3.7 (0.9–9.4) 4.0 (0.8–7.6) 4.9 (2.3–10.4)
Sex (M/F) 19/4 a, b 2/6 16/13
Septic shock (%) 23 (100) b 8 (100) 20 (69)
Vasopressor score 40 (15–60) b 35 (6–105) b 5 (0–18) a, c
PRISM score 25 (20–33) b 26 (18–35) b 17 (9–20) c
Survival (%) 16 (70) b 7 (88) 29 (100) c
IL-6 x 103 (pg/ml) < 0.01 135.0 (40.0–853.1) b 63.2 (15.1–70.5) 8.3 (1.1–80.9) c
Lactate (mmol/l) < 2.0 4.7 (3.1–6.9) b 4.0 (2.6–6.8) 3.0 (2.2–4.6) c
Glucose (mmol/l) 2.6–11.0 5.7 (4.1–7.7) b 7.8 (5.5–14.2) 7.7 (6.7–8.7) c
Cortisol (nmol/l) 200–800 * 620 (502–782) a, b 1173 (818–1263) 1089 (971–1346)
ACTH (pmol/l) < 11 * 146.1 (79.3–222.0) a, b 53.7 (10.8–116.0) 14.0 (5.6–64.2)
Cortisol/ACTH (nM/pM) 4.7 (2.3–8.4) a, b 20.7 (3.5–112.7) 89.4 (21.0–205.2)
11-deoxycortisol (nmol/l) < 50 * 181 (137–248) a, b 49 (36–69) 62 (44–88)
Cortisol/11-deoxycortisol 3.2 (2.1–4.3) a, b 21.6 (16.7–25.8) 19.2 (13.6–24.5)
All values are expressed as median (25th to 75th percentiles); * Non-stressed reference values (for cortisol morning values at 8:00 AM);
a Significantly different from children who were intubated without etomidate, p < 0.05; b Significantly different from patients who were not
intubated, p < 0.05; c Significantly different from patients who were intubated, independently of etomidate use, p < 0.05
disease severity parameters – such as PRISM score, IL-6,
and lactate levels – and vasopressor score than children
who were not intubated, whereas none of these parameters
significantly differed between children who were intu-
bated with or without etomidate (Table 1). Arterial glucose
levels were significantly lower in children who were
intubated with etomidate than in children who were not in-
tubated ( p = 0.023) and tended to be lower than in children
who were intubated without etomidate ( p = 0.082).
Adrenal function on admission
On admission, cortisol levels were significantly lower
and ACTH levels significantly higher with concomitantly
lower cortisol/ACTH ratios in children who were intu-
bated with etomidate than in those who did not receive
etomidate, independently of intubation (Table 1). Further-
more, children who were intubated with etomidate had
significantly higher 11-deoxycortisol levels with concomi-
tantly lower cortisol/11-deoxycortisol ratios than children
who did not receive etomidate, independently of intuba-
tion. Compared to non-stressed values, 11-deoxycortisol
levels were elevated in 95% of the children who received
etomidate and in 65% of the children who did not receive
etomidate ( p = 0.019), independently of intubation. Nei-
ther time from intubation to admission nor etomidate dose
per kilogram body weight correlated significantly with
serum levels of cortisol, ACTH, 11-deoxycortisol or their
ratios on admission (data not shown).
ANCOVA revealed ACTH levels to be significantly
related to intubation with etomidate and disease severity,
as shown by lactate levels (R2 = 0.54), whereas age and
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Fig. 2 Relation between ACTH and arterial lactate levels, depend-
ing on etomidate use. After adjustment for arterial lactate levels,
using ANCOVA, mean ACTH levels were 4.1 times higher in etomi-
date use ( p < 0.001). Children who received etomidate (•, continu-
ous line) and children who did not receive etomidate (◦, dotted line).
Data of children intubated without etomidate or those not intubated
were pooled, as they did not significantly differ
Fig. 3 Relation between cortisol and 11-deoxycortisol levels,
depending on etomidate use. After adjustment for 11-deoxycortisol
levels, using ANCOVA, mean cortisol levels were 3.2 times lower in
case of etomidate use ( p < 0.001). Children who received etomidate
(•, continuous line) and children who did not receive etomidate
(◦, dotted line). Data of children intubated without etomidate or
those not intubated were pooled, as they did not significantly differ
Fig. 4 Cortisol/ACTH ratios (a), cortisol/11-deoxycortisol ratios (b)
and cortisol levels (c) according to patients’ actual etomidate use
during the first 24 h after admission. The three profiles differed be-
tween the groups along time ( p < 0.001). Data shown are geomet-
ric means with standard errors. Children who received etomidate
(•, continuous line) and children who did not receive etomidate (◦,
dotted line). Within-group difference between successive time point
(a, p < 0.05). Between-group difference at time points (b, p < 0.05).
Numbers alongside data-points indicate numbers of children
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gender were not. When children were intubated with
etomidate, ACTH levels were 4.1 times higher for com-
parable lactate levels (Fig. 2). In contrast, we found no
difference in the relation of ACTH with lactate between
children who were intubated without etomidate and
those who were not intubated (ANCOVA, p = 0.222).
A similar pattern was found for ACTH levels with IL-6
levels and etomidate (R2 = 0.55), in which ACTH levels
were 3.3 times higher if children were intubated with
etomidate. ANCOVA revealed 11-deoxycortisol levels and
intubation with etomidate to be significantly related to
cortisol levels (R2 = 0.57), whereas age and gender were
not. Cortisol levels were 3.2 times lower, for comparable
11-deoxycortisol levels, if children were intubated with
etomidate (Fig. 3). In contrast, we found no difference in
the relation of cortisol with 11-deoxycortisol, between
children who were intubated without etomidate and those
who were not intubated (ANCOVA, p = 0.303).
Adrenal function time course
Within 5 h after study enrolment four further children
were intubated with etomidate. Seven children received
glucocorticoid treatment for suspected adrenal insuf-
ficiency after study enrolment; six of them (intubated
with etomidate) within 5 h and one (intubated without
etomidate) after 55 h. Eight children died due to hemody-
namic failure at median 11 h after PICU admission (range
8–43 h), seven of whom had received etomidate. Within
24 h both cortisol/ACTH and cortisol/11-dexoycortisol
ratios increased significantly in children who had received
etomidate, but not in children who did not receive etomi-
date, resulting in comparable cortisol/ACTH ratios with
still decreased cortisol/11-deoxycortisol ratios 24 h after
admission (Fig. 4).
Discussion
This retrospective study shows major differences in
ACTH, cortisol and 11-deoxycortisol levels between
children intubated with one single bolus of etomidate and
those who did not receive etomidate, independently of
intubation.
Although our study was not designed to investigate
the direct relation between etomidate administration and
adrenal function, we found significantly more signs of
impaired adrenal function, as shown by the combination of
significantly lower cortisol with increased ACTH levels,
in children who received etomidate than in those who did
not, even after correction for disease severity (Fig. 2). On
admission cortisol levels were 3.2 times lower and ACTH
levels were 4.1 times higher in children who received eto-
midate than in those who did not. Serum 11-deoxycortisol
(the precursor of cortisol that exerts no endocrine actions)
was significantly higher, and cortisol/11-deoxycortisol
lower, in children who received etomidate than in those
who did not, indicating impaired 11β-hydroxylase activity
(CYP11B1, Fig. 1). This is in accordance with in vitro
and in vivo studies that show etomidate to interfere
mainly with 11β-hydroxylase, and at higher concentra-
tions also with 11β- and 18-hydroxylase (CYP11B2)
and the cholesterol side-chain cleavage enzyme system
(CYP11A) [2, 14, 15–17]. Despite the fact that etomidate
is known to suppress adrenal function in a dose-dependent
manner in vitro [14], we did not find such a relation,
probably due to lack of study power. However, the dose
of etomidate was higher in children who died than in
those who survived. Because we studied the effect of
etomidate retrospectively in an uncontrolled setting, it is
difficult to report on relevant clinical deterioration, such
as persistent hypotension or the course of glucose levels.
We found, nevertheless, significantly lower glucose levels
on admission in children receiving etomidate than in those
who did not. Furthermore, in this study seven of the eight
children who died during admission received etomidate.
Significant but transient adrenocortical suppression 24 h
after a single bolus of etomidate has been described [18,
19]. Although we found cortisol concentrations and
cortisol/ACTH ratios to reach comparable levels between
the studied groups more than 24 h after intubation,
cortisol/11-deoxycortisol ratios were still significantly
decreased in children who received etomidate compared to
those who did not, indicating adrenocortical suppression
at the level of 11β-hydroxylase. Future investigations
using corticotropin test should be performed to study the
duration of this adrenocortical suppression.
In summary, our data imply that even one single
bolus of etomidate negatively influences adrenal function
for at least 24 h and therefore might increase risk of
death. As recently stated [6], considerable caution should
accompany the administration of etomidate in patients
with septic shock.
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